Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Pfizer’s (NYSE: PFE) Ibrance (palbociclib). This follows the company’s earlier approval for its active pharmaceutical ingredients (APIs) of palbociclib in China.
Palbociclib, initially approved in China in July 2018, saw its first generic version gain approval with Qilu Pharma in December 2020, followed by Hansoh Pharma’s (HKG: 3692) version in July 2022. The drug was subsequently included in the National Reimbursement Drug List (NRDL) at the end of 2022 through a price bidding process.- Flcube.com
